Stock Taper
SCREENER COMPARE ANY 2 STOCKS
RCUS
ARCUS BIOSCIENCES, INC.
NYSE
$29.66
▼ DOWN 1.56% (-0.47)

KEY STATISTICS

Market Cap$3.71 B
52w High$31.73
52w Low$11.04
Dividend Yield—
Frequency—
P/E-7.61
Volume736.98K
Shares Out.125.77M

COMPANY

LEADERSHIP

Terry J. Rosen
CHIEF EXECUTIVE
Terry J. Rosen

COMPENSATION 2026

Salary$775,000
Stock Awards$2,199,450
Incentive Plan Pay$658,750
All Other Comp.$14,753
Total$9,656,813

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 14, 2018
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
601

PRICE TARGET

Target High$47.00
Target Low$23.00
Target Median$42.50
Target Consensus$39.17

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$12.03M
OCT
27
TUE

PRICE

$29.66 ▼ DOWN 1.56% (−$0.47)
$29.60$29.80$30.009:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM29.66

About Arcus Biosciences, Inc.

https://arcusbio.com ↗

Arcus Biosciences is a clinical-stage biopharma developing cancer therapies like Etrumadenant, Zimberelimab, Domvanalimab, and others, with multiple trials and collaborations targeting various cancers.

INDUSTRY

Biotechnology

A PRODUCT ARCUS BIOSCIENCES, INC. IS KNOWN FOR

Casdatifan
Casdatifan

Casdatifan, Arcus Biosciences' lead oral small-molecule HIF-2α inhibitor, is prioritized for developing treatments for clear cell renal cell carcinoma, the most common kidney cancer.

COMPETITORS

COMPETITOR
AGEN COMPARE
AZN COMPARE
CGEN COMPARE
MRK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
License And RD Services$192M — — —
Other Collaboration Revenue— — $5M $25M ▲
License And Development Services— — $12M $16M ▲
RD Services$17M $0 ▼— —

ETFS HOLDING THIS STOCK

ETFS HOLDING
176
LISTED HERE
26
RANKED BY POSITION SIZE
XAW.TO
0.00% · 5.3M
VTI
0.00% · 2.8M
XBI
0.71% · 2.8M
XSMO
0.57% · 569.3K
SCHA
0.05% · 413.3K
FESM
0.16% · 350.8K
DFMC
0.13% · 338.3K
FYC
0.65% · 309.3K
LABU
0.47% · 91.8K
CANC
1.21% · 87.6K
XRSG.L
0.08% · 79.5K
CN
CNCR
3.32% · 62.8K
RSSL
0.09% · 42.9K
GSSC
0.07% · 25.8K
BBSC
0.10% · 24.3K
EES
0.09% · 22.1K
BBC
0.77% · 13.2K
ZSML.TO
0.15% · 8.3K
TILT
0.01% · 6.2K
URTY
0.03% · 3.5K
RFLR
0.11% · 3.5K
BKSE
0.12% · 3.4K
STXK
0.11% · 3.0K
VETS
0.15% · 1.8K
SMDX
0.01% · 602
USUE.DE
0.01% · 403

INSTITUTIONAL OWNERSHIP

SHARES OWNED
81.04%
HOLDERS
320
TOP 12 OF 320 · RANKED BY POSITION SIZE
Gilead Sciences, Inc.
31.4M sh · $427.38M
Blackrock, Inc.
16.4M sh · $506.11M
Blackrock Inc.
9.8M sh · $148.69M
Vanguard Group Inc
8.0M sh · $189.76M
Wellington Management Group Llp
6.1M sh · $131.53M
State Street Corp
6.0M sh · $185.89M
Suvretta Capital Management, LLC
5.2M sh · $123.65M
Point72 Asset Management, L.P.
4.3M sh · $58.92M
Fmr LLC
4.0M sh · $124.85M
Woodline Partners LP
3.8M sh · $81.6M
Marshall Wace, Llp
3.8M sh · $81.25M
Citadel Advisors LLC
3.1M sh · $96.65M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: CHIEF ACCOUNTING OFFICER
Azoy Alexander
Purchase · 2.8K shares
2026-08-21
★
OFFICER: CHIEF ACCOUNTING OFFICER
Azoy Alexander
Sale · 2.8K shares
2026-08-21
★
OFFICER: PRESIDENT
Jaen Juan C.
Sale · 268 shares
2026-07-10
★
OFFICER: PRESIDENT
Jaen Juan C.
Sale · 48.5K shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
EQUAL WEIGHT 2
OUTPERFORM 2
NEUTRAL 1
9 GRADES IN THE LAST 12 MONTHS
Wells Fargo EQUAL WEIGHT Wedbush OUTPERFORM HC Wainwright & Co. BUY Morgan Stanley EQUAL WEIGHT Goldman Sachs BUY Citigroup BUY Leerink Partners OUTPERFORM B of A Securities NEUTRAL

SECTORS PEERS

PEERPRICE
IBRX$8.04COMPARE
LQDA$68.43COMPARE
COGT$34.79COMPARE
DNLI$22.34COMPARE
BEAM$29.85COMPARE
VRDN$22.84COMPARE
OCUL$10.75COMPARE
AGIO$33.20COMPARE